X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
LL-BMT1 are contact lenses printed with bimatoprost which is a prostaglandin for the reduction of elevated IOP in patients with open angle glaucoma or ocular hypertension by selectively mimicking the effects of naturally occurring substances, prostamides.
Lead Product(s): Bimatoprost
Therapeutic Area: Ophthalmology Product Name: LL-BMT1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2024
Details:
LL-BMT1 (bimatoprost), a drug-eluting contact lens to treat glaucoma, and is preceded by the successful completion of the Company’s SIGHT-1 study that validated the MediPrint™ process and contact lenses for treating human subjects.
Lead Product(s): Bimatoprost
Therapeutic Area: Ophthalmology Product Name: LL-BMT1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 08, 2022
Details:
The funds raised in this Series A round are targeted primarily to support the upcoming Phase 2b clinical study along with the end of Phase 2 meeting with the FDA for its lead glaucoma asset, LL-BMT1 (bimatoprost) in patients with open angled glaucoma or ocular hypertension.
Lead Product(s): Bimatoprost
Therapeutic Area: Ophthalmology Product Name: LL-BMT1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $2.5 million Upfront Cash: Undisclosed
Deal Type: Series A Financing March 15, 2022
Details:
The expanded SAB will provide independent scientific review and guidance to the Company with regards to its R&D activities and product pipeline which includes company’s lead glaucoma asset as well as its products for dry eye, allergy, and other anterior segment conditions.
Lead Product(s): Bimatoprost
Therapeutic Area: Ophthalmology Product Name: LL-BMT1
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 05, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
